Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model-Reference-Cited by-同舟云学术

Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model

Published:2018-12 Issue:12 Volume:21 Page:1373-1381
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Hill-McManus Daniel,Marshall Scott,Soto Elena,Lane Steven,Hughes Dyfrig

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference49 articles.

1. Global epidemiology of gout: prevalence, incidence and risk factors;Kuo;Nat Rev Rheumatol,2015

2. The British Society for Rheumatology Guideline for the Management of Gout;Hui;Rheumatology,2017

3. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy;Shoji;Arthritis Rheum,2004

4. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout;Pascual;Ann Rheum Dis,2007

5. Allopurinol for chronic gout;Seth;Cochrane Database Syst Rev,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of economic evaluations in advancing HIV multipurpose prevention technologies in early-stage development;Frontiers in Reproductive Health;2024-04-18

2. Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: a systematic review;International Journal of Pharmacy Practice;2022-04-13

3. Combining Model‐Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design;CPT: Pharmacometrics & Systems Pharmacology;2020-12-31

4. High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?;Rheumatology and Therapy;2020-10-28

5. Linked Pharmacometric‐Pharmacoeconomic Modeling and Simulation in Clinical Drug Development;Clinical Pharmacology & Therapeutics;2020-10-26